Literature DB >> 27629685

[L'acidocétose diabétique euglycémique due à la canagliflozine: Une complication « acide » mais évitable de l'utilisation des inhibiteurs du cotransporteur sodium-glucose de type 2].

Maureen Clement1, Peter Senior2.   

Abstract

Entities:  

Year:  2016        PMID： 27629685      PMCID： PMC5023360     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  7 in total

1.  Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors.

Authors:  Julio Rosenstock; Ele Ferrannini
Journal:  Diabetes Care       Date:  2015-09       Impact factor: 19.112

2.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

3.  Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.

Authors:  Robert R Henry; Julio Rosenstock; Steven Edelman; Sunder Mudaliar; Alexandros-Georgios Chalamandaris; Sreeneeranj Kasichayanula; Allyson Bogle; Nayyar Iqbal; James List; Steven C Griffen
Journal:  Diabetes Care       Date:  2014-09-30       Impact factor: 19.112

4.  Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from Type 1 diabetes.

Authors:  T J McDonald; K Colclough; R Brown; B Shields; M Shepherd; P Bingley; A Williams; A T Hattersley; Sian Ellard
Journal:  Diabet Med       Date:  2011-09       Impact factor: 4.359

5.  Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.

Authors:  Anne L Peters; Elizabeth O Buschur; John B Buse; Pejman Cohan; Jamie C Diner; Irl B Hirsch
Journal:  Diabetes Care       Date:  2015-06-15       Impact factor: 19.112

6.  Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program.

Authors:  Ngozi Erondu; Mehul Desai; Kirk Ways; Gary Meininger
Journal:  Diabetes Care       Date:  2015-07-22       Impact factor: 19.112

7.  Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors.

Authors:  Wataru Ogawa; Kazuhiko Sakaguchi
Journal:  J Diabetes Investig       Date:  2015-09-06       Impact factor: 4.232
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.